Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users

Phase 1

Completed

• Conditions: Healthy; Drug Abuse
• Interventions: Drug: Placebo; Drug: Active Comparator #1; Drug: Active Comparator #2; Drug: Active Comparator #3; Drug: Lorcaserin Dose #1; Drug: Lorcaserin Dose #2; Drug: Lorcaserin Dose #3

• Registration Number: NCT00828659
• Lead Sponsor: Eisai Inc.

Brief Summary

The purpose of this study is to evaluate the abuse potential of lorcaserin in healthy recreational polydrug users.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-12
• Study First Submitted: 2009-01-22
• Study First Submitted QC: 2009-01-23
• Study First Posted: 2009-01-26
• Primary Completion: 2009-04
• Study Completion: 2009-04
• Status Verified: 2009-07
• Last Update Submitted: 2019-09-11
• Last Update Posted: 2019-09-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	-
Active Comparator #1	Active Comparator #1	-
Active Comparator #2	Active Comparator #2	-
Active Comparator #3	Active Comparator #3	-
Lorcaserin Dose #1	Lorcaserin Dose #1	-
Lorcaserin Dose #2	Lorcaserin Dose #2	-
Lorcaserin Dose #3	Lorcaserin Dose #3	-

Primary Outcome Measures

Name	Time	Method
To evaluate the abuse potential of lorcaserin

Secondary Outcome Measures

Name	Time	Method
To evaluate the safety and tolerability of lorcaserin

Trial Locations

Locations (1)

Kendle Early Phase, Toronto; 🇨🇦 Toronto, Ontario, Canada